Protagonist therapeutics, inc. (PTGX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-20,080

-17,501

-16,409

-29,174

-14,103

-13,865

-8,735

-8,663

-7,661

-3,052

-4,825

-14,979

-14,101

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,084

-7,098

-11,747

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

2,048

2,160

2,201

2,013

1,979

2,072

2,017

1,645

1,185

1,189

1,207

1,002

843

1,520

448

106

56

Operating lease right-of-use asset amortization

444

445

444

444

459

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

217

202

195

176

130

128

151

170

78

117

108

93

88

75

83

86

73

Amortization of debt issuance costs and accretion of debt discount

45

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities, net of premium amortization

164

197

188

115

94

98

-194

10

-120

-190

-225

-150

-122

-35

-10

10

-82

Foreign currency remeasurement loss

549

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred tax asset

183

773

-102

-1,626

180

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value associated with redeemable convertible preferred stock tranche liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,194

Change in fair value of redeemable convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

525

Changes in operating assets and liabilities:
Research and development tax incentive receivable

162

-

-

-

441

332

-1,059

357

606

460

-2,009

377

102

-

-

-

-

Research and development tax incentive receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

199

455

575

Receivable from collaboration partner - related party

-3,161

4,810

-2,944

-172

474

1

-1,198

3,062

906

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-806

1,234

-218

1,398

406

-591

281

343

-1,150

1,367

664

-112

-1,586

1,621

1,317

-191

-943

Accounts payable

913

1,165

-1,167

-3,694

696

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

21

-

-332

1,579

-151

-272

72

-508

593

Payable to collaboration partner - related party

-146

242

210

-401

150

297

488

-103

379

-

-

-

-

-

-

-

-

Accrued expenses and other payables

-700

1,879

-462

2,734

-3,053

665

-2,738

3,010

974

1,522

1,754

158

1,359

2,190

1,003

-415

617

Deferred revenue - related party

-2,485

2,852

-2,889

34,566

-1,222

253

-5,232

-8,678

-9,872

-

-

-

-

-

-

-

-

Operating lease liability

477

476

478

468

463

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,848

-14,289

-14,246

3,670

-16,662

-10,135

-9,276

-15,398

-15,138

-14,149

40,704

-12,327

-10,356

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of marketable securities

20,883

49,129

65,348

30,733

21,726

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of available-for-sale securities

-

-

-

-

-

-

-

-

25,636

-

20,152

0

8,002

66,773

0

6,396

0

Proceeds from maturities of marketable securities

63,751

36,793

33,000

18,400

26,000

23,724

23,000

23,035

4,000

16,200

19,570

13,465

6,800

2,500

3,900

390

7,398

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,980

-8,073

-5,239

Purchases of property and equipment

138

218

-309

892

166

62

148

68

208

56

190

372

48

52

16

28

251

Net cash provided by investing activities

42,730

-12,554

-32,039

-13,225

4,108

4,549

9,917

9,591

-21,844

4,752

-772

13,093

-1,250

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance costs related to issuance of long-term debt

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan

406

14

1,288

87

390

2

328

74

530

218

328

87

374

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

143

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,884

-6,034

7,147

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

20

22,488

Net cash provided by financing activities

399

9,779

25,237

10,630

390

479

23,032

74

530

65,062

31

87

374

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

85,278

-750

22,631

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-72

-125

100

-9

8

-

-

-

-

-31

67

-5

115

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

27,209

-17,189

-20,948

1,066

-12,156

-5,194

23,563

-5,713

-36,452

55,634

40,030

848

-11,117

-

-

-

-

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Effect of exchange rate changes on cash and cash equivalents

-72

-125

100

-9

8

-

-

-

-

-31

67

-5

115

-83

74

-4

35

Net (decrease) increase in cash and cash equivalents

27,209

-17,189

-20,948

1,066

-12,156

-5,194

23,563

-5,713

-36,452

55,634

40,030

848

-11,117

-74,940

82,256

-14,861

24,574

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING INFORMATION:
Purchases of property and equipment in accounts payable and accrued liabilities

5

-57

75

-567

649

-

-

-28

36

-

-36

-76

118

21

0

0

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

293

225

40

Deferred offering costs in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

561

135

Tenant improvement allowance reimbursement

-

-

-

0

469

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of fair value of redeemable convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,837